Day: March 19, 2026

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the year ended December 31, 2025. Summary Results(thousands of dollars)  except share and per share amounts   2025     2024         Revenue $ 137,506   $ 141,946  EBITDA (1) $ 7,461   $ 9,712  EBITDA (1) margin   5.4%     6.8%  EBITDA (1) per share $ 0.06   $ 0.07  Capital expenditures $ 5,221   $ 3,848  Net income (loss) attributable to common shareholder $ 6,417   $ (24,442 )Net income (loss) attributable to common shareholder per share $ 0.05   $ (0.19 )       Weighted average shares outstanding, net   131,131,598     131,131,598         (1) EBITDA is considered a non-GAAP measure. Refer to “EBITDA Reconciliation” below for a reconciliation...

HAMILTON, BERMUDA, March 19, 2026 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the “SEC”). The report and the audited financial statements are available on DHT’s website www.dhtankers.com and in the attachment included with this press release. Shareholders may request a hard copy of the audited financial statements free of charge by sending an e-mail to info@dhtankers.com.   About DHT Holdings, Inc.DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations...

— Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 — — Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 — — Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy — — $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to support operations into 1Q27– WESTLAKE VILLAGE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Genelux Corporation...

– Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 – – Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 – – Friedreich’s Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events – – CPVT (SGT-501): Clinical sites activated for Phase 1b ARTEMIS first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic...

— DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 — — Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 — BOSTON, March 19, 2026 (GLOBE NEWSWIRE) — Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. “At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders....

Alpha successfully returned to flight in March, as Firefly enters 2026 with new national security SciTec contracts.“Stairway to Seven” launching from Firefly’s Space Launch Complex 2 at Vandenberg Space Force Base in California on March 11, 2026. CEDAR PARK, Texas, March 19, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today issued financial results for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a transformative year in Firefly’s history, as we more than doubled our annual revenue while executing across multiple launch, spacecraft, and ground programs and strengthening our portfolio of space exploration and national security space capabilities,” said Jason Kim, CEO of Firefly Aerospace. “Our laser...

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — Gemini Space Station, Inc. (“Gemini”) (NASDAQ: GEMI) today reported its fourth quarter and full year 2025 financial results in a shareholder letter and earnings presentation which can be found on its Investor Relations website at https://investors.gemini.com. Management will host a conference call at 8:30 am ET tomorrow, March 20, to discuss the results. The event will be webcast live via our Investor Relations website or via this link. Following the call, a replay and transcript will also be available at https://investors.gemini.com. Channels for Disclosure of Information As a reminder, we announce material information to the public through filings with the Securities and Exchange Commission (SEC), the investor relations page on our website (investors.gemini.com), the blog on our website...

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended...